Table 2.
In vitro antitumor activities of target compounds 5a–m and 7a–e.
| Compound | IC50 (μmol/L) a, b | |||||
|---|---|---|---|---|---|---|
| A549 | SGC-7901 | HepG2 | MCF-7 | HCT-8 | Hk-2 | |
| 5a | 2.57 ± 0.48 | 3.28 ± 0.67 | 7.06 ± 0.27 | 2.34 ± 0.48 | 1.56 ± 0.45 | <1.0 |
| 5b | >40 | >40 | 21.86 ± 0.75 | 25.27 ± 6.072 | >40 | - |
| 5c | >40 | 19.30 ± 1.28 | 14.23 ± 2.38 | 31.34 ± 0.62 | 34.07 ± 1.38 | - |
| 5d | 1.12 ± 0.09 | 0.90 ± 0.12 | 0.99 ± 0.12 | 1.59 ± 0.58 | 0.48 ± 0.06 | <1.0 |
| 5e | >40 | >40 | >40 | >40 | >40 | |
| 5f | 3.82 ± 0.31 | 2.17 ± 0.24 | 1.02 ± 0.44 | 1.68 ± 0.21 | 4.49 ± 0.24 | <10 |
| 5g | 4.05 ± 1.99 | 9.04 ± 1.17 | 5.01 ± 1.27 | 3.60 ± 0.92 | 5.79 ± 1.24 | <10 |
| 5h | >40 | >40 | 14.95 ± 1.52 | >40 | >40 | - |
| 5i | >40 | 16.92 ± 0.12 | 6.96 ± 1.02 | >40 | >40 | - |
| 5j | 15.34 ± 4.87 | 10.01 ± 1.21 | 4.68 ± 0.66 | 11.16 ± 3.75 | 24.23 ± 1.07 | - |
| 5k | >40 | 13.45 ± 0.93 | 2.04 ± 0.71 | 9.26 ± 1.00 | >40 | - |
| 5l | >40 | >40 | >40 | 21.87 ± 2.16 | >40 | - |
| 5m | >40 | 10.67 ± 0.40 | 3.56 ± 1.03 | 2.35 ± 0.65 | 2.84 ± 1.88 | - |
| 7a | >40 | 13.95 ± 2.79 | 3.14 ± 1.33 | 3.12 ± 1.31 | >40 | - |
| 7b | >40 | >40 | >40 | >40 | >40 | - |
| 7c | >40 | 1.29 ± 0.32 | 1.94 ± 0.74 | 1.56 ± 1.00 | 3.53 ± 0.91 | <10 |
| 7d | >40 | 32.09 ± 1.23 | >40 | >40 | >40 | - |
| 7e | >40 | >40 | >40 | >40 | >40 | - |
| aloe-emodin | 16.38 ± 2.82 | 10.78 ± 3.54 | 3.61 ± 0.81 | 10.8 ± 0.41 | 16.33 ± 0.67 | - |
| etoposide | 3.18 ± 1.36 | 8.30 ± 1.09 | 5.77 ± 0.99 | 5.45 ± 1.14 | 3.40 ± 0.42 | - |
a IC50 values are shown as mean ± SD from the average of three replicates; b IC50: concentration that causes a 50% reduction in cell growth; “-”: not detected.